Cannabist Co. Buys Time, But Debt Crisis Signals Industry-Wide Distress

CHELMSFORD, Mass. – January 30, 2026 – The Cannabist Company, one of the largest and most established multi-state cannabis operators in the United States, has entered a high-stakes forbearance agreement with its senior lenders, temporarily staving off default while casting a harsh spotlight on the profound financial pressures gripping the American cannabis industry.

The company, formerly known as Columbia Care, announced today that it had secured the agreement after electing not to make interest payments due on December 31, 2025. The missed payments, totaling millions on two sets of senior secured notes, triggered an event of default following a 30-day grace period. The deal, struck with an ad hoc group of noteholders representing over 75% of the outstanding debt, prevents lenders from taking action until February 17, 2026. This brief window gives the distressed company precious time to negotiate a path forward, with options ranging from further asset sales to a comprehensive debt restructuring.

In a statement, The Cannabist Company framed the decision to withhold payment as a strategic move “to enhance its short-term financial flexibility and preserve liquidity” as it navigates a challenging market. However, the move underscores a severe cash crunch for a company with a sprawling footprint of 77 facilities, including 61 dispensaries, across 12 U.S. jurisdictions.

A High-Stakes Countdown to Restructure

The forbearance agreement puts a hard deadline on a complex problem. With less than three weeks until the February 17th expiration, The Cannabist Company, its advisors, and the noteholders are locked in critical discussions. The company's future hinges on their ability to reach a long-term solution. Should these negotiations fail, and no extension be granted, the lenders would be free to exercise their full rights, which could include accelerating the entire debt load and seizing company assets pledged as collateral.

Such a scenario could force the company into a formal bankruptcy proceeding. The financial metrics paint a grim picture, suggesting this is a distinct possibility. The company’s Altman Z-Score, a widely used predictor of bankruptcy risk, sits at a deeply negative -3.3, placing it firmly in the distress zone. This is compounded by a quick ratio of 0.48, indicating it has less than half the liquid assets needed to cover its short-term liabilities.

This financial distress comes despite recent, aggressive moves to raise cash. Just last month, the company announced the sale of its Virginia assets to an affiliate of Millstreet Credit Fund LP for $130 million. That deal itself was a pivot from a previously announced, less lucrative agreement with rival Curaleaf. The company has explicitly stated that proceeds from such sales are intended for debt reduction, but the forbearance agreement suggests these measures have not been sufficient to stabilize its balance sheet.

A Bellwether for a Distressed Industry

The Cannabist Company’s predicament is not an isolated incident but rather a symptom of a systemic illness affecting many of America’s largest cannabis operators. The industry is teetering on a “financial cliff,” with an estimated $3 billion in debt set to mature by the end of 2026. For years, multi-state operators (MSOs) funded rapid expansion through high-interest debt, betting on federal legalization and exponential market growth that have been slow to materialize.

Now, that debt is coming due in a far harsher economic environment. The combination of rising interest rates and the continued federal illegality of cannabis has created a perfect storm. Because cannabis remains a Schedule I controlled substance, companies are barred from accessing traditional banking services and capital markets. They are also crippled by Section 280E of the federal tax code, which prohibits them from deducting standard business expenses, leading to exorbitant effective tax rates that drain cash flow.

This capital-starved environment forces companies to rely on private lenders and debt instruments with punishing interest rates. The Cannabist Company’s own notes carry rates over 9%. As one industry analyst noted, “The ‘grow at all costs’ model funded by expensive debt is over. Lenders are no longer patient, and they want to see a clear path to profitability and repayment, not just a hope for federal reform.” The failure of adult-use legalization efforts in key states has further dampened revenue projections, leaving many MSOs over-leveraged and under-capitalized.

From Balance Sheets to Storefronts

While negotiations unfold in corporate boardrooms, the consequences of this financial instability could soon be felt on the ground. The Cannabist Company’s vast network of dispensaries and production facilities employs thousands of workers and serves countless medical and adult-use customers. The company’s strategy of “footprint optimization” has already led to significant market exits.

In late 2024, the company completed the sale of all 14 of its Florida dispensaries and two production facilities for a mere $5 million, citing an unprofitable and “unbalanced” portfolio in the state. This retreat from one of the nation’s largest medical cannabis markets demonstrates the difficult choices leadership is facing. The ongoing financial pressure raises questions about the operational stability of its remaining 61 retail locations.

Potential impacts could include reduced inventory, scaled-back operations, and a pause on facility development. For employees, the uncertainty brings concerns about job security, especially after a corporate restructuring initiative was launched in 2024 to generate $10 million in annual savings. For consumers, the turmoil could affect product availability and brand reliability in the dozen jurisdictions where The Cannabist Company operates its retail brand and manufactures popular product lines like Seed & Strain and Triple Seven.

A Strategy of Contraction

Under the leadership of CEO David Hart, who took the helm in 2024, the company has pivoted from aggressive expansion to strategic contraction. The stated mandate for 2025 was to “simplify our business, maintain liquidity, improve margins, and drive cash flow generation.” The sales of the Virginia and Florida assets are the most visible components of this strategy, aimed at shedding non-core or underperforming operations to fortify the balance sheet.

This marks a significant reversal from the industry’s land-grab era. Even a previous debt maturity extension, secured in early 2025, proved to be a temporary patch rather than a permanent fix. Now, with a market capitalization that has plummeted to around $21 million and a stock price trading in the pennies, the company has little room left to maneuver.

The coming weeks will be a crucial test of this survival strategy. The outcome of negotiations with noteholders will not only determine the fate of The Cannabist Company but will also serve as a powerful signal for other debt-laden MSOs navigating the same treacherous financial landscape. Whether the company can engineer a sustainable path forward or becomes another casualty of the industry’s capital crisis remains to be seen.